A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
Anaplastic thyroid carcinoma
Lenvatinib
Survival period
Journal
Auris, nasus, larynx
ISSN: 1879-1476
Titre abrégé: Auris Nasus Larynx
Pays: Netherlands
ID NLM: 7708170
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
26
08
2020
revised:
01
10
2020
accepted:
12
10
2020
pubmed:
29
10
2020
medline:
20
4
2022
entrez:
28
10
2020
Statut:
ppublish
Résumé
Anaplastic thyroid carcinoma (ATC) accounts for 1-2% of all malignant thyroid tumors. There are only a small number of patients with ATC and most of them die within 6 months after diagnosis, making it difficult to establish a standard treatment strategy. Although multimodal therapy, including radical surgery, radiotherapy, and chemotherapy, has been introduced, the survival rate remains poor. The use of molecular-targeted drugs for cancer therapy has become widely popular. Lenvatinib, a new molecular-targeted anticancer drug, is a multi-targeted receptor tyrosine kinase inhibitor (TKI). We report a rare case of a patient with ATC (T4N0M0) who responded extremely well to the administration of lenvatinib after radical surgery. Although ATC is one of the most fatal neoplasms, lenvatinib is a promising drug.
Identifiants
pubmed: 33109426
pii: S0385-8146(20)30273-X
doi: 10.1016/j.anl.2020.10.005
pii:
doi:
Substances chimiques
Phenylurea Compounds
0
Quinolines
0
lenvatinib
EE083865G2
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
515-519Informations de copyright
Copyright © 2020. Published by Elsevier B.V.